Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ADXN logo ADXN
Upturn stock ratingUpturn stock rating
ADXN logo

Addex Therapeutics Ltd (ADXN)

Upturn stock ratingUpturn stock rating
$7.9
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/27/2025: ADXN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $30

1 Year Target Price $30

Analysts Price Target For last 52 week
$30 Target price
52w Low $6.51
Current$7.9
52w High $11.84

Analysis of Past Performance

Type Stock
Historic Profit -54.5%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 9.22M USD
Price to earnings Ratio -
1Y Target Price 30
Price to earnings Ratio -
1Y Target Price 30
Volume (30-day avg) 1
Beta 1.99
52 Weeks Range 6.51 - 11.84
Updated Date 08/28/2025
52 Weeks Range 6.51 - 11.84
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -7.46

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 3521.74%
Operating Margin (TTM) -853.23%

Management Effectiveness

Return on Assets (TTM) -25.09%
Return on Equity (TTM) -163.15%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 5783675
Price to Sales(TTM) 37.44
Enterprise Value 5783675
Price to Sales(TTM) 37.44
Enterprise Value to Revenue 27.25
Enterprise Value to EBITDA -0.76
Shares Outstanding 1069140
Shares Floating 26107116
Shares Outstanding 1069140
Shares Floating 26107116
Percent Insiders -
Percent Institutions 0.03

ai summary icon Upturn AI SWOT

Addex Therapeutics Ltd

stock logo

Company Overview

overview logo History and Background

Addex Therapeutics Ltd (ADXN) is a pharmaceutical company pioneering allosteric modulation-based drug discovery and development. Founded in 2002 in Geneva, Switzerland, it initially focused on research partnerships. Over time, it has transitioned towards developing its own pipeline of novel small molecule allosteric modulators for neurological disorders and other diseases. Significant milestones include progressing lead compounds through clinical trials and securing strategic collaborations.

business area logo Core Business Areas

  • Neurology: Focuses on developing treatments for neurological disorders, including Parkinson's disease and other movement disorders.
  • Allosteric Modulator Platform: Leverages its proprietary platform to discover and develop novel allosteric modulators targeting GPCRs and other receptors.

leadership logo Leadership and Structure

The leadership team comprises experienced professionals in drug discovery, clinical development, and business management. The company operates with a matrix structure, organizing teams around specific therapeutic programs and functional areas.

Top Products and Market Share

overview logo Key Offerings

  • Dipraglurant (ADX71149): A negative allosteric modulator of the mGluR5 receptor being developed for treatment of dyskinesia associated with Parkinson's disease. Market share data is currently in clinical trial phase, therefore, there is no current market share. Competitors include other companies developing treatments for Parkinson's related movement disorders.
  • ADX88178: A positive allosteric modulator of GABA-B receptor being developed for treatment of Schizophrenia. This is also in clinical trials. Competitors include existing antipsychotic medications and companies developing novel treatments for Schizophrenia.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive and research-intensive, with significant investment in drug discovery and clinical development. Growth is driven by unmet medical needs, aging populations, and technological advancements. Increasing regulatory scrutiny and pricing pressures pose challenges.

Positioning

Addex Therapeutics Ltd positions itself as a leader in allosteric modulation, offering a differentiated approach to drug discovery. Its competitive advantage lies in its proprietary platform and expertise in developing novel small molecule modulators.

Total Addressable Market (TAM)

The total addressable market (TAM) for Addex's target indications (e.g., Parkinson's disease dyskinesia, Schizophrenia) is substantial, potentially exceeding tens of billions of dollars. Addex's positioning is focused on addressing unmet needs within these markets using its novel allosteric modulation approach.

Upturn SWOT Analysis

Strengths

  • Proprietary allosteric modulator platform
  • Experienced management team
  • Promising clinical pipeline
  • Strategic partnerships

Weaknesses

  • Limited financial resources
  • High R&D costs
  • Regulatory approval risks
  • Dependence on strategic partnerships

Opportunities

  • Expanding clinical pipeline
  • Out-licensing or partnering programs
  • Entering new therapeutic areas
  • Capitalizing on growing market for neurological disorders

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Regulatory hurdles
  • Pricing pressures

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • TEVA
  • LLY
  • VRTX

Competitive Landscape

Addex faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its innovative allosteric modulation platform.

Growth Trajectory and Initiatives

Historical Growth: Historical growth trends are dependent on pipeline progress and partnership achievements.

Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization efforts.

Recent Initiatives: Recent initiatives include advancing lead compounds through clinical trials, securing strategic collaborations, and expanding the intellectual property portfolio.

Summary

Addex Therapeutics is a developing pharmaceutical company pioneering allosteric modulation. Its platform and clinical pipeline offer potential, but its limited financial resources and dependence on partnerships are risk factors. Successfully advancing its lead compounds through clinical trials is critical for future growth. The company faces competition from larger, well-established pharmaceutical firms and needs to overcome significant regulatory hurdles.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Third-Party Market Research Reports
  • ClinicalTrials.gov

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on publicly available information and estimates, and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Addex Therapeutics Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2020-01-29
Co-Founder, CEO & Director Mr. Timothy Mark Dyer
Sector Healthcare
Industry Biotechnology
Full time employees 2
Full time employees 2

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.